BID | 64.31 | ASK | 69.00 | ||
Open | 66.02 | Previous Close | 64.97 | ||
Pre-Market | - | After-Market | - | ||
- -% | - - |
Target Price | 61.09 | Analyst Rating | Strong Buy 1.35 | |
Potential % | -6.10 | Finscreener Ranking | ★★★ 49.58 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★ 45.74 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★ 39.68 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 40.52 | Earnings Rating | Strong Buy | |
Market Cap | 11.77B | Earnings Date | 1st Nov 2023 | |
Alpha | -0.00 | Standard Deviation | 0.16 | |
Beta | 1.46 |
Today's Price Range 64.9767.98 | 52W Range 40.73100.77 | 5 Year PE Ratio Range -54.20-28.40 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Neutral |
Performance | |||
---|---|---|---|
1 Week | -0.49% | ||
1 Month | 10.16% | ||
3 Months | -21.44% | ||
6 Months | -19.82% | ||
1 Year | 57.73% | ||
3 Years | -46.26% | ||
5 Years | -16.57% | ||
10 Years | 429.80% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -21.52 | |||
ROE last 12 Months | -23.73 | |||
ROA (5Y Avg) | -4.94 | |||
ROA last 12 Months | -12.00 | |||
ROC (5Y Avg) | -14.88 | |||
ROC last 12 Months | -12.34 | |||
Return on invested Capital Q | -2.59 | |||
Return on invested Capital Y | -3.75 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 8.10 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-11.50 | ||||
2.70 | ||||
6.83 | ||||
364.30 | ||||
-18.90 | ||||
-1.71 | ||||
-6.91 | ||||
17.50 | ||||
10.16B | ||||
Forward PE | -54.09 | |||
PEG | -0.22 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.00 | ||||
2.50 | ||||
0.44 | ||||
0.79 | ||||
-54.30 | ||||
Leverage Ratio | 2.00 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
72.80 | ||||
-35.60 | ||||
-26.00 | ||||
-46.60 | ||||
-32.38 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.53B | ||||
8.62 | ||||
44.08 | ||||
64.93 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | -0.49 | 0.00 | 100.00 |
Q02 2023 | -0.50 | -0.45 | 10.00 |
Q01 2023 | -0.79 | -0.42 | 46.84 |
Q04 2022 | -0.90 | -0.72 | 20.00 |
Q03 2022 | -1.10 | -0.84 | 23.64 |
Q02 2022 | -1.07 | -0.94 | 12.15 |
Q01 2022 | -1.12 | -1.04 | 7.14 |
Q04 2021 | -0.91 | -1.28 | -40.66 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | -0.53 | 1.85 | Positive |
12/2023 FY | -1.48 | 22.11 | Positive |
3/2024 QR | -0.40 | -2.56 | Negative |
12/2024 FY | -1.22 | 4.69 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -0.49 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.35M |
Shares Outstanding | 180.85K |
Shares Float | 178.50M |
Trades Count | 26.33K |
Dollar Volume | 89.16M |
Avg. Volume | 1.19M |
Avg. Weekly Volume | 687.65K |
Avg. Monthly Volume | 1.51M |
Avg. Quarterly Volume | 1.38M |
Exact Sciences Corporation (NASDAQ: EXAS) stock closed at 65.06 per share at the end of the most recent trading day (a 0.14% change compared to the prior day closing price) with a volume of 1.35M shares and market capitalization of 11.77B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 5000 people. Exact Sciences Corporation CEO is Kevin T. Conroy.
The one-year performance of Exact Sciences Corporation stock is 57.73%, while year-to-date (YTD) performance is 31.41%. EXAS stock has a five-year performance of -16.57%. Its 52-week range is between 40.73 and 100.77, which gives EXAS stock a 52-week price range ratio of 40.52%
Exact Sciences Corporation currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 2.70, a price-to-sale (PS) ratio of 6.83, a price to cashflow ratio of 364.30, a PEG ratio of -0.22, a ROA of -12.00%, a ROC of -12.34% and a ROE of -23.73%. The company’s profit margin is -32.38%, its EBITDA margin is -26.00%, and its revenue ttm is $1.53 Billion , which makes it $8.62 revenue per share.
Of the last four earnings reports from Exact Sciences Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Exact Sciences Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Exact Sciences Corporation is Strong Buy (1.35), with a target price of $61.09, which is -6.10% compared to the current price. The earnings rating for Exact Sciences Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Exact Sciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Exact Sciences Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.93, ATR14 : 2.84, CCI20 : 68.38, Chaikin Money Flow : -0.10, MACD : 0.03, Money Flow Index : 39.74, ROC : 9.09, RSI : 50.97, STOCH (14,3) : 61.22, STOCH RSI : 0.04, UO : 38.32, Williams %R : -38.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Exact Sciences Corporation in the last 12-months were: Brian Baranick (Sold 0 shares of value $0 ), Brian Baranick (Sold 2 770 shares of value $170 643 ), Condella Sarah (Option Excercise at a value of $0), Condella Sarah (Sold 21 574 shares of value $1 562 325 ), Conroy Kevin (Option Excercise at a value of $0), Conroy Kevin (Sold 34 324 shares of value $2 186 371 ), Coward D. (Option Excercise at a value of $0), Coward D. (Sold 6 981 shares of value $436 430 ), Cunningham Everett (Sold 0 shares of value $0 ), Cunningham Everett (Sold 16 635 shares of value $1 089 808 ), Doyle James (Option Excercise at a value of $90 480), Doyle James (Sold 3 402 shares of value $288 135 ), Doyle James Edward (Sold 2 000 shares of value $194 840 ), Elliott Jeffrey (Option Excercise at a value of $0), Elliott Jeffrey (Sold 8 687 shares of value $545 550 ), Everett V. Cunningham (Option Excercise at a value of $0), Everett V. Cunningham (Sold 3 628 shares of value $224 972 ), Herriott James (Sold 1 300 shares of value $130 000 ), James E. Doyle (Option Excercise at a value of $90 480), James Herriott (Option Excercise at a value of $0), James Herriott (Sold 3 023 shares of value $185 652 ), Jeffrey T. Elliott (Option Excercise at a value of $0), Jeffrey T. Elliott (Sold 8 687 shares of value $545 550 ), Kevin T. Conroy (Option Excercise at a value of $0), Kevin T. Conroy (Sold 34 324 shares of value $2 186 371 ), Napier Katherine (Sold 3 027 shares of value $273 974 ), Orville Jacob (Option Excercise at a value of $0), Orville Jacob (Sold 20 496 shares of value $1 373 232 ), Sarah Condella (Option Excercise at a value of $0), Sarah Condella (Sold 8 987 shares of value $564 035 ), Scott D. Coward (Option Excercise at a value of $0), Scott D. Coward (Sold 6 981 shares of value $436 430 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
CEO: Kevin T. Conroy
Telephone: +1 608 284-5700
Address: 441 Charmany Drive, Madison 53719, WI, US
Number of employees: 5 000
Tue, 28 Nov 2023 13:20 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Exact Sciences (EXAS) and Regeneron (REGN)
- TipRanks. All rights reserved.Tue, 31 Oct 2023 10:55 GMT Exact Sciences (EXAS) Receives a Hold from Benchmark Co.
- TipRanks. All rights reserved.Mon, 23 Oct 2023 13:10 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Elevance Health (ELV)
- TipRanks. All rights reserved.Wed, 02 Aug 2023 14:40 GMT Analysts Top Healthcare Picks: Exact Sciences (EXAS), IQVIA Holdings (IQV)
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.